🟢 Rocket Pharmaceuticals Inc is trading 5.3% up today after closing the $180 million sale of its Priority Review Voucher

Rocket Pharmaceuticals Inc is trading 5.3% up at $2.80 following the announcement that it has closed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV).

• The company received $180 million in non-dilutive gross proceeds from the sale, significantly strengthening its balance sheet.
• Pro forma cash, cash equivalents, and investments are now approximately $322.6 million, which is expected to fund operations into the second quarter of 2028.
• The PRV was granted by the FDA in March 2026 in connection with the approval of KRESLADI™, the company's gene therapy for a rare immunodeficiency.